LT3452039T - Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais - Google Patents

Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais

Info

Publication number
LT3452039T
LT3452039T LTEPPCT/US2017/031142T LTUS2017031142T LT3452039T LT 3452039 T LT3452039 T LT 3452039T LT US2017031142 T LTUS2017031142 T LT US2017031142T LT 3452039 T LT3452039 T LT 3452039T
Authority
LT
Lithuania
Prior art keywords
deuteronated
treatment
hair loss
jak inhibitors
loss disorder
Prior art date
Application number
LTEPPCT/US2017/031142T
Other languages
English (en)
Lithuanian (lt)
Inventor
Amanda Wagner
James Cassella
Philip Graham
Virginia BRAMAN
Vinita UTTAMSINGH
Jana VON HEHN
Colleen Hamilton
Original Assignee
Sun Pharmaceutical Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3452039(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sun Pharmaceutical Industries, Inc. filed Critical Sun Pharmaceutical Industries, Inc.
Publication of LT3452039T publication Critical patent/LT3452039T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2017/031142T 2016-05-04 2017-05-04 Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais LT3452039T (lt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662331827P 2016-05-04 2016-05-04
US201662338869P 2016-05-19 2016-05-19
US201662418774P 2016-11-07 2016-11-07
US201662419237P 2016-11-08 2016-11-08
US201662434404P 2016-12-14 2016-12-14
US201762466358P 2017-03-02 2017-03-02
US201762492758P 2017-05-01 2017-05-01
PCT/US2017/031142 WO2017192905A1 (en) 2016-05-04 2017-05-04 Treatment of hair loss disorders with deuterated jak inhibitors

Publications (1)

Publication Number Publication Date
LT3452039T true LT3452039T (lt) 2024-10-25

Family

ID=60203616

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/031142T LT3452039T (lt) 2016-05-04 2017-05-04 Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais

Country Status (21)

Country Link
US (3) US10561659B2 (OSRAM)
EP (2) EP4424367A3 (OSRAM)
JP (3) JP7145080B2 (OSRAM)
KR (3) KR20250070139A (OSRAM)
CN (1) CN109069493A (OSRAM)
AU (3) AU2017261286B2 (OSRAM)
BR (1) BR112018072339A2 (OSRAM)
CA (1) CA3022519A1 (OSRAM)
DK (1) DK3452039T3 (OSRAM)
ES (1) ES2988629T3 (OSRAM)
FI (1) FI3452039T3 (OSRAM)
HR (1) HRP20241345T1 (OSRAM)
HU (1) HUE068643T2 (OSRAM)
LT (1) LT3452039T (OSRAM)
MX (6) MX388054B (OSRAM)
PL (1) PL3452039T3 (OSRAM)
PT (1) PT3452039T (OSRAM)
RS (1) RS66006B1 (OSRAM)
SI (1) SI3452039T1 (OSRAM)
SM (1) SMT202400389T1 (OSRAM)
WO (1) WO2017192905A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250070139A (ko) * 2016-05-04 2025-05-20 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 저해제를 이용한 탈모 장애의 치료
US12325707B2 (en) * 2019-02-06 2025-06-10 Sun Pharmaceutical Industries, Inc. Process for preparing enantiomerically enriched JAK inhibitors
WO2021236139A1 (en) 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
WO2022094133A1 (en) * 2020-10-28 2022-05-05 Concert Pharmaceuticals, Inc. Regimens for the treatment of hair loss disorders with deuterated jak inhibitors
CN116916927A (zh) * 2020-10-28 2023-10-20 太阳医药工业公司 用于用氘化jak抑制剂治疗脱发症的方案
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
WO2023018904A1 (en) 2021-08-11 2023-02-16 Concert Pharmaceuticals, Inc. Treatment of hair loss disorders with deuterated jak inhibitors
AU2022328282A1 (en) 2021-08-12 2024-02-22 Sun Pharmaceutical Industries, Inc. Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors
EP4518863A1 (en) 2022-05-04 2025-03-12 Sun Pharmaceutical Industries, Inc. Dosage regimens for treatment with deuterated jak inhibitors
US12364699B2 (en) * 2023-10-10 2025-07-22 Sun Pharmaceuticals Industries, Inc. Method of treating hair loss disorders
US12247034B1 (en) * 2024-04-19 2025-03-11 Sun Pharmaceutical Industries, Inc. Crystalline form of deuruxolitinib phosphate

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
BR0209325A (pt) 2001-05-03 2004-07-20 Hoffmann La Roche Forma de dosagem farmacêutica de mesilato de nelfinavir amorfo
KR20070083839A (ko) 2004-09-29 2007-08-24 코디스 코포레이션 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
RS55940B1 (sr) 2005-12-28 2017-09-29 Vertex Pharma Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
EP2635299B1 (en) * 2010-11-02 2019-07-31 The Trustees of Columbia University in the City of New York Methods for treating hair loss disorders
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
HUE040127T2 (hu) 2012-03-29 2019-02-28 Univ Columbia Eljárások hajhullási rendellenességek kezelésére
SMT202500302T1 (it) * 2012-06-15 2025-09-12 Sun Pharmaceutical Industries Inc Derivati deuterati del ruxolitinib
EP2882751B1 (en) * 2012-07-30 2018-06-27 Concert Pharmaceuticals Inc. Deuterated ibrutinib
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物
US10166183B2 (en) * 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
KR20250070139A (ko) 2016-05-04 2025-05-20 썬 파마슈티칼 인더스트리즈 인코포레이티드 중수소화된 jak 저해제를 이용한 탈모 장애의 치료

Also Published As

Publication number Publication date
JP7145080B2 (ja) 2022-09-30
BR112018072339A2 (pt) 2019-02-19
PT3452039T (pt) 2024-10-07
AU2017261286B2 (en) 2023-03-23
SMT202400389T1 (it) 2024-11-15
EP3452039B1 (en) 2024-07-03
AU2023201112A1 (en) 2023-03-30
MX2023002323A (es) 2023-03-22
EP3452039A1 (en) 2019-03-13
MX2023002321A (es) 2023-03-22
KR20190003711A (ko) 2019-01-09
US20190160068A1 (en) 2019-05-30
AU2023201112B2 (en) 2025-05-08
HRP20241345T1 (hr) 2024-12-20
MX2021014175A (es) 2022-01-04
AU2017261286A1 (en) 2018-11-22
JP2025026895A (ja) 2025-02-26
DK3452039T3 (da) 2024-10-07
KR20230086814A (ko) 2023-06-15
MX2018013347A (es) 2019-09-02
JP2022171838A (ja) 2022-11-11
US12076323B2 (en) 2024-09-03
MX388054B (es) 2025-03-19
EP4424367A3 (en) 2024-11-13
HUE068643T2 (hu) 2025-01-28
FI3452039T3 (fi) 2024-10-02
WO2017192905A1 (en) 2017-11-09
EP4424367A2 (en) 2024-09-04
KR20250070139A (ko) 2025-05-20
CA3022519A1 (en) 2017-11-09
AU2025213576A1 (en) 2025-08-21
ES2988629T3 (es) 2024-11-21
MX2023002325A (es) 2023-03-22
MX2023002324A (es) 2023-03-22
PL3452039T3 (pl) 2024-11-18
RS66006B1 (sr) 2024-10-31
US20200222408A1 (en) 2020-07-16
EP3452039A4 (en) 2019-12-25
SI3452039T1 (sl) 2024-12-31
CN109069493A (zh) 2018-12-21
US20240423986A1 (en) 2024-12-26
KR102810262B1 (ko) 2025-05-19
JP7586868B2 (ja) 2024-11-19
JP2019516684A (ja) 2019-06-20
US10561659B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
LT3452039T (lt) Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais
IL263680A (en) Combination therapies
PL3265053T3 (pl) Sposoby leczenia skóry
IL246678A0 (en) Azepane derivatives and methods of treating hepatitis b infections
IL263030A (en) Pegylated liposomes and methods of use
HUE056287T2 (hu) Pancreatitis kezelése
EP3487523A4 (en) THERAPEUTIC APPLICATIONS OF THE CPF1-BASED GENOME EDITION
PL3283527T3 (pl) Leczenie skojarzone nowotworów
EP4212536C0 (en) BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
IL263802A (en) Cancer treatment combinations
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
IL254876A0 (en) Treatment of lung cancer with inhibitors of glutaminase
PT3622953T (pt) Tratamento combinado do cancro
PL3493812T3 (pl) Połączenia imetelstatu i wenetoklaksu do leczenia ostrej białaczki szpikowej
PL3289672T3 (pl) Sposoby i urządzenia do tworzenia przeplatanych zespołów falistych cewek
EP3503904A4 (en) ASCAROSIDE TREATMENT OF EOSINOPHILIC OESOPHAGITIS
PL3393468T3 (pl) Metody leczenia niedoboru odporności
DK3307267T3 (da) Behandling af multipel sklerose
IL257764B (en) Methods for treatment of diseases
DK3532076T3 (da) Immunterapeutiske behandlinger af tumorer
IL313083A (en) Terlipressin compositions and their methods of use
IL280343A (en) Treatment of mucopolysaccharidosis iva